TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03518112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: PO or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV
Study: NCT02839993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Study: NCT02718287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting intervention PCCSF (220 clusters)
Description: Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting without PCCSF (220 clusters)
Description: Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
Study: NCT03518112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02674633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKL-T01
Description: Videogame-like digital therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AKL-T09
Description: Videogame-like digital therapy
Study: NCT00493064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: topical eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: topical eye drops
Study: NCT01684215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
Study: NCT02784340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine and Fentany

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivicaine and Fentany
Study: NCT00778739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
Study: NCT01546155

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: Up to a 120 minute PET scan using \[11C\]diprenorphine as the radiotracer
Study: NCT01544140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral syrup 7.5 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral tablets, 800 mg, single dose
Study: NCT02824939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane (TAP) Block
Description: 0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum (QL) Block
Description: 0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
Study: NCT03392558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Skin Care Regimen
Description: Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Regimen
Description: Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
Study: NCT00954707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel & Aspirin, Prasugrel & Aspirin
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Aspirin
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Study: NCT04630457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ankle prosthesis
Description: At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ankle prosthesis
Description: At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Meridium® (Microprocessor ankle prosthesis)
Description: There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
Study: NCT00977431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Day 1 to day 42
Study: NCT02784340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25G spinal needles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25G spinal needles
Study: NCT00977431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Day 1 to day 42
Study: NCT02784340

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 25G spinal needles
Study: NCT03410160

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and biochemical examination.
Description: Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and biochemical examination.
Description: Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
Study: NCT03586973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablet
Study: NCT00977431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
Study: NCT00338130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Oral liquid or Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: oral
Study: NCT02487082

Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin and Donepezil
Description: 10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.

Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin and Donepezil
Description: 10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: For both groups: 5 weeks of Placebo in the Run-In Phase. For Group B: an addition 5 weeks of Placebo in Phase 1.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: For both groups: 5 weeks of Placebo in the Run-In Phase. For Group B: an addition 5 weeks of Placebo in Phase 1.
Study: NCT00813826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC022
Description: SLC022 150 mg capsule, 900mg daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule, TID
Study: NCT03451006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral metformin (up to 2gm) will be given in divided doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Placebo will be given in divided doses
Study: NCT02117388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Therapy
Description: Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
Study: NCT03708016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot gait training
Description: Lokomat robot training was applied to stroke patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot gait training
Description: Lokomat robot training was applied to stroke patients.
Study: NCT00908219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
Study: NCT04333017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency ablation of parietal endometriosis
Description: Treatment is carried out under local anaesthesia after surgical asepsis, in interventional radiology room. Radiofrequency needles are inserted percutaneously under ultrasound guidance. Number of needles depends on the size of lesion (1 or 2 or 3 needles). In case of proximity between lesion and peritoneum, artificial ascites can be performed. Treatment is carried out in accordance with device's instructions for use (thyroid nodules treatment algorithm), with a gradual increase in power every 5 minutes, without exceeding the maximum authorised power (depending on number and length of needles). State of coagulation is monitored under visual ultrasound control of ablation area (diffusion of Co bubbles), until a decrease in effective power is obtained. Several ablation zones are performed on the same nodule with overlapping of the different impacts. An ice pack is applied to the treated area. An analgesic PO treatment of step 1 and/or 2 is prescribed for 5 days.
Study: NCT03015064

Intervention type: OTHER
Intervention: Myocardial Infarction
Description: Observational study of myocardial Infarction patients
Study: NCT01337765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 + MEK162
Study: NCT03708016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulation
Description: tDCS brain stimulation on leg motor areas was applied to stroke patients.
Study: NCT04654234

Intervention type: DEVICE
Intervention: Total body PET/CT (uExplorer)
Description: A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
Study: NCT03902899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention (oral presentation)
Description: A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
Study: NCT00003130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT00855075

Intervention type: DEVICE
Intervention: Cerebral State Monitor
Description: A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
Study: NCT02137694

Intervention type: OTHER
Group type: OTHER
Intervention: vaginal auto-takings and urinary test
Description: vaginal auto-takings and urinary test
Study: NCT02343354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/physical activity intervention
Description: Please see arm description
Study: NCT00503230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Intervention (SCI)
Description: Standard Care Intervention (SCI)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally Tailored Intervention (CTI)
Description: Culturally Tailored Intervention (CTI)
Study: NCT01470417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + ChemoRadiotherapy
Description: Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
Study: NCT04628845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endo-perio therapy with laser 940nm
Description: Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Endo-perio therapy without laser 940nm
Description: Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
Study: NCT00730951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: 500mg Capsulated Ground Dried Korean Red Ginseng Root
Study: NCT03964532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
Study: NCT00942981

Intervention type: DRUG
Intervention: PET
Description: Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.

Intervention type: DRUG
Intervention: PET
Description: Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.
Study: NCT03049462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B Complex Plus Vitamin C Tablets
Description: Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: B Complex Plus Vitamin C Tablets
Description: Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
Study: NCT01626742

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ready to Drink Flavored Beverage
Description: 2 servings a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to drink flavored beverage w/ AN 777
Description: 2 servings a day
Study: NCT01689948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home rehabilitation therapy
Description: 12 sessions of home rehabilitation therapy
Study: NCT03237702

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Carotenoids
Description: All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
Study: NCT02965716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IL